Premature ejaculation treatment: behavioral, topical and off-label options

Status: No prescription medicine is FDA-approved for premature ejaculation in the US, and paroxetine is FDA-approved for other conditions, not for PE. Source: Drugs@FDA and the PAXIL label, checked 2026-10-17.

The short version: premature ejaculation (PE) has several treatments with real evidence behind them. The 2020 guideline from the American Urological Association (AUA) and the Sexual Medicine Society of North America (SMSNA) names three groups as first-line medicines: daily SSRIs, a few on-demand options, and topical numbing products. It also supports counseling and behavioral methods, alone or combined with medicine (AUA/SMSNA Disorders of Ejaculation Guideline, 2020). In the US, the oral medicines are used off-label, and the over-the-counter sprays and creams follow FDA monograph rules. This page walks through each option, what the evidence shows and what to ask a clinician.

What treatments exist for premature ejaculation?

Treatments fall into four groups: behavioral techniques, counseling, topical numbing products and oral prescription medicines. The AUA/SMSNA guideline recommends daily SSRIs, on-demand clomipramine or dapoxetine (where available) and topical penile anesthetics as first-line medicines (Strong Recommendation), and it advises that combining behavioral and medicine approaches “may be more effective than either modality alone” (AUA/SMSNA guideline, Statements 9 and 13). Which one fits depends on whether PE has been present from the start or developed later, on other health conditions and on personal preference.

Sources: AUA/SMSNA guideline; Sathianathen et al., Cochrane, 2021; 21 CFR Part 348; ANAFRANIL label.

Do behavioral techniques and counseling help?

They can, though the research is thinner than for medicines. A systematic review of 10 randomized trials (521 men) found “limited evidence” that physical techniques such as squeeze, stop-start and sensate focus improve outcomes compared with a waitlist, and that adding behavioral therapy to medicine gave better results than medicine alone in three trials (Cooper et al., Sexual Medicine, 2015). A Cochrane review of psychosocial treatments was more cautious, calling the evidence “weak and inconsistent” and noting most trials were small (Melnik et al., Cochrane, 2011).

The AUA/SMSNA guideline still recommends that clinicians “consider referring men with premature ejaculation to a mental health professional with expertise in sexual health” (Moderate Recommendation) (AUA/SMSNA guideline, Statement 8). For men whose concern is occasional, or whose timing falls within the normal range, the guideline favors education and psychosexual therapy over medicine. The Cochrane review authors note that psychological issues are present in most men with PE, as a cause or as a consequence (Melnik et al., Cochrane, 2011). Our guides on telling ED from performance anxiety and overcoming performance anxiety cover that side, and ED and depression covers mood.

What are the topical products for premature ejaculation?

Topical products are numbing agents that reduce sensitivity and are applied before sex. FDA rules for over-the-counter “male genital desensitizer” products allow two active ingredients: benzocaine in a water-soluble base and lidocaine in a metered spray. The rules define these as products “applied to the penis to help in temporarily slowing the onset of ejaculation” (21 CFR 348.3 and 348.10). Their required warnings say that PE “may be due to a condition requiring medical supervision,” and that use should stop if either partner develops a rash or irritation, such as burning or itching (21 CFR 348.50).

On the evidence, a meta-analysis of 9 randomized trials found topical anesthetics more effective than placebo, and in single trials lidocaine gel outperformed paroxetine and sildenafil on time to ejaculation. The authors also note that most trials were of “unclear” quality (Martyn-St James et al., Sexual Health, 2016). The same review notes that EMLA, a lidocaine-prilocaine mixture, is recommended for off-label use in PE (Martyn-St James et al., 2016). How much to use and when are set by the product label or the prescriber.

Is any pill FDA-approved for premature ejaculation in the US?

No. As of this check, no prescription pill is FDA-approved to treat PE in the US. Dapoxetine, a short-acting SSRI developed for PE, received an FDA “not-approvable” letter in 2005 and was later approved in other countries (McMahon, Clinical Medicine Insights: Reproductive Health, 2011). A search of FDA’s own Drugs@FDA database returns no dapoxetine application (Drugs@FDA, checked 2026-10-17). That is why the guideline lists it as first-line only “where available.”

The pills US clinicians do use for PE, such as SSRIs and clomipramine, are FDA-approved for other conditions and prescribed off-label. Products sold online as “PE pills” without a prescription are a different matter: the FDA has found hidden prescription drug ingredients in many sexual enhancement products, which our page on FDA tainted supplement warnings tracks.

What does off-label use of paroxetine mean?

Off-label means a medicine approved for one use is prescribed for another. The FDA explains that once a drug is approved, health care providers “generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate,” but that FDA “has not determined that the drug is safe and effective for the unapproved use” (FDA, Understanding Unapproved Use of Approved Drugs “Off Label”). Paroxetine (PAXIL) is approved for major depressive disorder, OCD, panic disorder, social anxiety disorder, generalized anxiety disorder and PTSD, and PE is not on that list (PAXIL label, Section 1).

The reason it is used for PE comes from its side effects. The label warns that in men, SSRI use “may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction,” and in its trials ejaculatory disturbance was reported by 13% to 28% of men on paroxetine against 0% to 2% on placebo (PAXIL label, Sections 5.11 and 6.1). The same label carries a boxed warning about suicidal thoughts and behaviors in pediatric and young adult patients, lists drugs it must not be combined with, and warns about symptoms after stopping abruptly. Those are reasons this decision belongs with a prescriber, who also sets any amount and schedule.

Source: Sathianathen et al., Cochrane Database of Systematic Reviews, 2021. The review covers SSRIs as a group, not paroxetine alone.

Can ED medicines help when both occur?

When PE and erectile dysfunction (ED) occur together, the guideline says to treat the ED. The AUA/SMSNA guideline states that clinicians “should treat comorbid erectile dysfunction in patients with premature ejaculation according to the AUA Guidelines on Erectile Dysfunction,” and that for acquired PE, treating a specific cause such as ED comes first, alone or with PE treatment (AUA/SMSNA guideline, Statement 12 and the pharmacotherapy introduction). Our guide to how ED medications work explains that medicine class.

For PE on its own, ED medicines (PDE5 inhibitors) are used off-label. A meta-analysis of 15 trials found them more effective than placebo, and found that adding one to an SSRI worked better than an SSRI alone. The authors flag high variation between studies and trials of mostly “unclear” quality (Martyn-St James et al., European Urology Focus, 2017). PDE5 inhibitors are not on the guideline’s first-line list for PE without ED.

What about supplements and other alternative treatments?

The guideline says the evidence is not there yet. The AUA/SMSNA panel advises that clinicians tell patients “there is insufficient evidence to support the use of alternative therapies,” and that surgery, including bulking-agent injections, should be considered experimental and used only within an approved clinical trial (AUA/SMSNA guideline, Statements 14 and 15). A systematic review of acupuncture and herbal products found only “preliminary evidence” from small studies of unclear quality, with sparse safety data (Cooper et al., Sexual Medicine, 2017).

When should you talk to a clinician?

Talk to a clinician if early ejaculation is frequent, bothers you or your partner, or started after a period of normal timing. The guideline asks clinicians to take a medical, relationship and sexual history and do a focused exam. It advises against extra testing for lifelong PE and allows it, as clinically indicated, for PE that developed later (AUA/SMSNA guideline, Statements 3, 5 and 6). Our guide to talking to a doctor about ED has tips for starting that conversation, which apply here too.

Sources

Every clinical statement on this page traces to one of these sources:

• American Urological Association and Sexual Medicine Society of North America, Disorders of Ejaculation: An AUA/SMSNA Guideline (2020). Statements 1 to 15 on premature ejaculation, including evaluation, referral, first-line medicines, combined treatment, comorbid ED and alternative therapies: auanet.org, disorders of ejaculation guideline
• 21 CFR Part 348, External Analgesic Drug Products for Over-the-Counter Human Use (eCFR, current as of 2026-10-15). Definition, permitted ingredients and required warnings for male genital desensitizers: ecfr.gov, 21 CFR Part 348
• PAXIL (paroxetine) prescribing information, DailyMed (Apotex). Section 1 indications, boxed warning, Section 4 contraindications, Section 5.11 sexual dysfunction and Table 8 male sexual adverse reactions: dailymed.nlm.nih.gov, PAXIL label
• ANAFRANIL (clomipramine) prescribing information, DailyMed (SpecGx). Indication for obsessive-compulsive disorder: dailymed.nlm.nih.gov, ANAFRANIL label
• U.S. Food and Drug Administration, Understanding Unapproved Use of Approved Drugs “Off Label”: fda.gov, off-label use
• U.S. Food and Drug Administration, Drugs@FDA database. No application found for dapoxetine, checked 2026-10-17: accessdata.fda.gov, Drugs@FDA
• Sathianathen NJ, et al. Selective serotonin re-uptake inhibitors for premature ejaculation in adult men (Cochrane Database of Systematic Reviews, 2021). 31 trials, 8,254 men: pubmed.ncbi.nlm.nih.gov/33745183
• Cooper K, et al. Behavioral Therapies for Management of Premature Ejaculation: A Systematic Review (Sexual Medicine, 2015). 10 trials, 521 men: pubmed.ncbi.nlm.nih.gov/26468381
• Melnik T, et al. Psychosocial interventions for premature ejaculation (Cochrane Database of Systematic Reviews, 2011): pubmed.ncbi.nlm.nih.gov/21833964
• Martyn-St James M, et al. Topical anaesthetics for premature ejaculation: a systematic review and meta-analysis (Sexual Health, 2016). 9 trials: pubmed.ncbi.nlm.nih.gov/26599522
• Martyn-St James M, et al. Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis (European Urology Focus, 2017). 15 trials: pubmed.ncbi.nlm.nih.gov/28720356
• Cooper K, et al. Complementary and Alternative Medicine for Management of Premature Ejaculation: A Systematic Review (Sexual Medicine, 2017). 10 trials: pubmed.ncbi.nlm.nih.gov/28041925
• McMahon CG. Efficacy of dapoxetine in the treatment of premature ejaculation (Clinical Medicine Insights: Reproductive Health, 2011). Regulatory history, including the 2005 FDA not-approvable letter: pubmed.ncbi.nlm.nih.gov/24453509